OverviewSuggest Edit

Cerecor is a clinical-stage biopharmaceutical company, which develops drugs to treat patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

TypePublic
Founded2011
HQRockville, US
Websitecerecor.com

Latest Updates

Employees (est.) (Dec 2019)18(-71%)
Revenue (FY, 2019)$6.8 M(-63%)
Share Price (Sept 2020)$2.7 (-2%)
Cybersecurity ratingAMore

Key People/Management at Cerecor

James A. Harrell

James A. Harrell

Chief Commercial Officer
Garry Neil

Garry Neil

Chief Medical Officer
H. Jeffrey Wilkins

H. Jeffrey Wilkins

Chief Medical Officer
Show more

Cerecor Office Locations

Cerecor has an office in Rockville
Rockville, US (HQ)
540 Gaither Rd #400
Show all (1)

Cerecor Financials and Metrics

Cerecor Revenue

Cerecor's revenue was reported to be $6.75 m in FY, 2019
USD

Revenue (Q2, 2020)

1.3m

Gross profit (Q2, 2020)

1.3m

Gross profit margin (Q2, 2020), %

94.2%

Net income (Q2, 2020)

(13.3m)

EBIT (Q2, 2020)

(11.8m)

Market capitalization (16-Sept-2020)

211.3m

Closing stock price (16-Sept-2020)

2.7

Cash (30-Jun-2020)

45.4m
Cerecor's current market capitalization is $211.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

27.8m18.3m6.8m

Cost of goods sold

635.6k7.5m566.5k

Gross profit

27.2m10.8m6.2m

Gross profit Margin, %

98%59%92%
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

25.0m4.5m4.8m4.1m5.4m4.4m5.6m2.8m1.3m

Cost of goods sold

863.6k1.4m3.1m1.9m141.8k1.4m66.6k77.6k

Gross profit

3.6m3.4m963.5k3.5m4.3m4.2m2.7m1.3m

Gross profit Margin, %

81%70%24%64%97%74%98%94%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

21.2m5.1m2.5m10.6m3.6m

Accounts Receivable

3.3m3.2m1.0m

Prepaid Expenses

703.2k1.5m707.0k

Inventories

401.6k391.3k382.2k1.1m21.3k
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

3.3m16.6m11.9m8.8m3.0m5.5m24.0m2.5m2.2m6.8m16.1m9.4m5.3m5.7m45.4m

Accounts Receivable

2.8m3.3m3.0m2.7m2.9m5.0m2.2m2.0m

Prepaid Expenses

105.1k231.5k542.0k210.0k249.6k402.3k341.0k774.3k954.5k1.3m1.2m865.1k1.7m777.4k823.9k

Inventories

3.4m1.5m1.1m1.0m617.6k402.3k16.3k12.2k
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.5m)(16.5m)11.9m(40.1m)(16.1m)

Depreciation and Amortization

23.5k26.9k425.5k4.6m3.9m

Inventories

2.7m(202.6k)(311.2k)532.9k

Accounts Payable

(268.7k)332.1k96.1k82.5k1.0m
USDQ3, 2015

Debt/Equity

-0.2 x

Debt/Assets

1.2 x

Financial Leverage

-0.2 x
Show all financial metrics

Cerecor Acquisitions / Subsidiaries

Company NameDateDeal Size
Ichorion TherapeuticsSeptember 28, 2018$27 m

Cerecor Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Cerecor Online and Social Media Presence

Embed Graph

Cerecor News and Updates

Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome

ROCKVILLE, Md., March 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announces that it will explore the role of an inflammatory cytok…

Cerecor Reports 2019 Results

-Company Transformed Into Orphan and Rare Disease Biotech-Clear Corporate Strategy with New Leadership-Significant Advancement in Pipeline and Regulatory Milestones

Cerecor to Acquire Aevi Genomic Medicine

PHILADELPHIA, Dec. 5, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. ("Aevi") (Nasdaq: GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. ("Cerecor") (Nasdaq: CERC) pursuant to which Aevi will merge with a wholly owned subsidiary of Cerecor in an...

Cerecor Reports Third Quarter 2019 Results

ROCKVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases  and neurology, announced today its financial results for the third quarter ended September…

Cerecor Closes Deal to Sell Pediatric Portfolio

ROCKVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today that it has closed the sale of its pediatric portfolio of as…

Cerecor To Sell Pediatric Portfolio to AYTU BioScience

-Deal Valued in Excess of $32 Million-Eliminates Debt Associated with Avadel / Deerfield Agreement-Provides Non-Dilutive Cash Generation to Fund R&D  -Extends Runway Towards NDA Submission of CERC-801
Show more

Cerecor Blogs

Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) g…

Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS

Top-line Data Anticipated in Fourth Quarter 2020 ROCKVILLE, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced t…

Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares

ROCKVILLE, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today the closing of the previously announced underwritten of…

Cerecor Inc. Announces Pricing of $33,000,000 Public Offering of Common Stock

ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it has entered into an underwriting agreement with…

Cerecor Inc. Announces Proposed Public Offering of Common Stock

ROCKVILLE, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it intends to offer for sale shares of its common …

Cerecor to Present at the Jefferies Virtual Healthcare Conference

ROCKVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 2:30 p.m. EDT. A live webcast of the presentation ca…
Show more

Cerecor Frequently Asked Questions

  • When was Cerecor founded?

    Cerecor was founded in 2011.

  • Who are Cerecor key executives?

    Cerecor's key executives are James A. Harrell, Garry Neil and H. Jeffrey Wilkins.

  • How many employees does Cerecor have?

    Cerecor has 18 employees.

  • What is Cerecor revenue?

    Latest Cerecor annual revenue is $6.8 m.

  • What is Cerecor revenue per employee?

    Latest Cerecor revenue per employee is $375 k.

  • Who are Cerecor competitors?

    Competitors of Cerecor include Vitality Biopharma, Mylan and Horizon Therapeutics.

  • Where is Cerecor headquarters?

    Cerecor headquarters is located at 540 Gaither Rd #400, Rockville.

  • Where are Cerecor offices?

    Cerecor has an office in Rockville.

  • How many offices does Cerecor have?

    Cerecor has 1 office.